Potential Impact of KarXT on Negative Symptoms in Acute Schizophrenia

DX'd - Other
1

‘‘Effect of KarXT on Negative Symptoms in the Full Sample and Subgroup With Prominent Negative Symptoms
• In the full sample, KarXT (n=314) was associated with a significantly greater improvement from baseline to week 5
in PANSS Marder negative factor score compared with placebo (n=326) (least squares mean [LSM] difference=-1.97,
standard error [SE]=0.40, P<0.0001; Cohen’s d=0.42; Figure 2A)
• A total of 64 participants (10%) met criteria for having prominent negative symptoms at baseline. In this subgroup,
KarXT (n=29) was associated with a significantly greater reduction from baseline to week 5 in PANSS Marder negative
factor score compared with placebo (n=35) (LSM difference=-4.71, SE=1.16, P<0.0001; Cohen’s d=1.18) (Figure 2B)’’

3 Likes
2

So karxt is good for negative symptoms?

1 Like
3

Apparently yes. But until there is clinical evidence it cannot be confirmed. Everything seems to indicate that it will be much more tolerable than current antipsychotics.

4 Likes
4

Wooohooo good news

2 Likes
5

I swear I can’t wait to get that medicine in my hands.

3 Likes
6

Its suppose to be approved in September I wonder how long after approval until its on the market? Im in the US and planning on taking it right away

1 Like
7

It would be nice to have a psych med that actually lives up to the hype.

3 Likes
8

The United States has excellent logistics. In 2 or 3 months it would be supplying the local US market. At least that’s what my psychologist told me.

2 Likes